Lactylation Antibodies Uncover Novel Mechanisms of Tumor Ferroptosis Resistance: A Literature Analysis

1. Literature Information

• Research Topic: Lactylation-mediated SUMO2 modification drives ferroptosis resistance in lung adenocarcinoma
• Core Finding: SUMO2-K11 lactylation regulates ACSL4 stability to inhibit ferroptosis, promoting tumor progression and chemotherapy resistance
• Key Tools: Lactylation antibodies (pan-specific and site-specific) from ANT BIO PTE. LTD.
• Application Scenarios: Tumor metabolism, ferroptosis research, post-translational modification analysis, and prognostic biomarker development

2. Research Background

Protein lactylation, a newly identified post-translational modification (PTM), involves the covalent attachment of lactate to lysine residues via lactyltransferases. Initially characterized on histones, lactylation links cellular metabolic status to gene expression regulation. In recent years, accumulating evidence has expanded its scope to non-histone proteins, revealing its involvement in diverse cellular processes.

In the tumor microenvironment, the Warburg effect induces enhanced glycolysis in cancer cells, leading to excessive lactate accumulation—creating an abundant substrate pool for protein lactylation. Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, has emerged as a promising therapeutic target for cancer. However, tumor cells frequently develop resistance to ferroptosis, severely limiting the efficacy of ferroptosis-inducing therapies.

A critical knowledge gap existed regarding whether and how lactylation, a metabolism-linked PTM, contributes to ferroptosis resistance. This study aimed to address this gap, with lactylation antibodies from ANT BIO PTE. LTD. serving as core tools to dissect the underlying molecular mechanisms.

3. Research 

1. Metabolic Reprogramming Analysis: Investigate whether ferroptotic stress induces lactate accumulation and lactylation modification in lung adenocarcinoma cells using metabolomics and lactylation detection.
2. Key Target Identification: Screen for lactylation-modified proteins associated with ferroptosis via lactylome analysis, focusing on conserved and tumor-specific modification sites.
3. Functional Validation: Construct gene-edited cell lines (e.g., SUMO2-K11R point mutation) to assess the impact of specific lactylation events on ferroptosis sensitivity.
4. Mechanistic Exploration: Elucidate the downstream signaling pathways of lactylation, particularly its interaction with ferroptosis-related proteins (e.g., ACSL4).
5. Clinical Correlation: Analyze the association between lactylation modification levels and patient prognosis in clinical lung adenocarcinoma samples.

4. Research Results

1. Ferroptosis Induces Lactylation: Treatment with ferroptosis inducers significantly upregulates intracellular lactate levels and global protein lactylation in lung adenocarcinoma cells. Exogenous lactate supplementation enhances ferroptosis resistance by reducing lipid peroxidation and increasing antioxidant capacity.
2. SUMO2-K11 Lactylation as a Key Target: Lactylome analysis identifies SUMO2-K11 as the most dynamically regulated lactylation site, which is evolutionarily conserved and specifically expressed in lung cancer tissues.
3. SUMO2-K11 Lactylation Promotes Ferroptosis Resistance: SUMO2-K11R mutant cells exhibit increased sensitivity to ferroptosis inducers, with higher lipid reactive oxygen species (ROS) levels, elevated malondialdehyde (MDA) content, and reduced glutathione (GSH)/oxidized glutathione (GSSG) ratio.
4. Clinical Prognostic Value: In 140 lung adenocarcinoma patient tissues, high SUMO2-K11 lactylation (SUMO2-K11la) correlates with low 4-hydroxynonenal (a lipid peroxidation marker) expression and shorter overall survival. It remains an independent poor prognostic factor in post-chemotherapy patients.
5. Molecular Mechanism: SUMO2-K11la weakens the interaction between SUMO2 and ACSL4 (a key ferroptosis executor), inhibiting ACSL4 SUMOylation and promoting its degradation via the ubiquitin-proteasome pathway. This reduces polyunsaturated fatty acid esterification and pro-ferroptotic lipid synthesis.

5. Product Empowerment

ANT BIO PTE. LTD.’s STARTER brand lactylation antibodies played an indispensable role in every critical step of this research:

1. Pan-Lactylation Antibody (STARTER Sub-Brand): Enabled initial screening of global lactylation level changes via Western blot, providing direct evidence for ferroptosis-induced lactylation reprogramming. Its high sensitivity ensured the detection of subtle changes in lactylation abundance.
2. Site-Specific Lactylation Antibody (STARTER Sub-Brand): The anti-SUMO2-K11la antibody, developed with high specificity, allowed precise detection of the target modification site. It facilitated functional validation and clinical sample analysis, including immunohistochemical staining of patient tissues.
3. Core Advantages of the Products:
• High modification specificity: Cross-validated with modified/unmodified peptides, showing no cross-reactivity with other acylations (e.g., acetylation, crotonylation).
• Excellent affinity: Efficiently enriches and detects endogenous lactylated proteins, even at low expression levels.
• Batch-to-batch consistency: Strict quality control ensures stable performance

6．Brand Mission

ANT BIO PTE. LTD. is a leading provider of life science reagents, offering a comprehensive portfolio including antibodies, proteins, kits, and general laboratory reagents. We operate three specialized sub-brands:

• Absin: Focuses on general reagents and kits for broad experimental applications.
• Starter: Specializes in high-quality antibodies, including post-translational modification-specific antibodies like lactylation antibodies.
• UA: Concentrates on recombinant proteins for functional studies and drug development.

Guided by the principle of "Empowering Scientific Discovery Through Precision Reagents," we adhere to strict international quality standards (EU 98/79/EC, ISO9001, ISO13485) and advanced development platforms (e.g., recombinant antibody technology, multi-system protein expression). Our mission is to provide researchers worldwide with reliable, high-performance tools and professional technical support, accelerating breakthroughs in cancer research, metabolism, epigenetics, and other frontier fields to advance human health.

7．Related Product List

8．AI Disclaimer

This article is AI-compiled and interpreted based on the original work. All intellectual property (e.g., images, data) of the original publication shall belong to the journal and the research team. For any infringement, please contact us promptly and we will take immediate action.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.